证券代码：000078 证券简称：海王生物 深圳市海王生物工程股份有限公司 投资者关系活动记录表 编号：2023-001 投资者关系活动类别 ☑特定对象调研 □分析师会议 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 参与单位名称 长城证券、浙商证券、中天证券、红荔湾基金、铭海基金、天襄 资本、万方达资产、个人投资者杨帆 时间 2023 年 5 月 11 日 15：30-17：30 地点 深圳市南山区科技园科技中三路 1 号海王银河科技大厦 24 楼 上市公司接待人员姓名 副总裁兼董事局秘书王云雷先生 财务部副总监李爽女士 证券事务代表林健怡女士 1、2022 年年报显示，公司在计提商誉减值后还有 17.46 亿元的 商誉，这部分未来有什么计划？ 答：根据《企业会计准则》的要求，公司每年会聘请专业的 投资者关系活动主要内 评估机构出具评估报告，以此来判断子公司是否存在商誉减值的 容介绍 情况。商誉的可收回金额是按照预计未来现金流量测算而来，是 基于公司历史年度的经营情况并结合基准日时点公司现状、市场 环境、行业政策及行业发展趋势等，据此预测公司未来五年及稳 定期的预计未来现金流。当公 ...

Financial Performance - Total operating revenue for Q1 2023 was CNY 9,957,850,383.56, an increase of 8.22% compared to CNY 9,201,630,764.82 in the same period last year[13] - Net profit attributable to shareholders was CNY 74,530,706.41, reflecting a growth of 5.08% from CNY 70,927,976.38 year-on-year[17] - The company reported a net profit of 110,250,475.24, an increase from 100,718,458.35 in the previous period, representing a growth of approximately 1.57%[35] - The company’s total comprehensive income attributable to shareholders was 74,530,706.41, compared to 70,927,976.38 in the previous period, indicating an increase of approximately 5.67%[36] - The company’s basic earnings per share were reported at 0.0271, compared to 0.0269 in the previous period, indicating a slight increase of about 0.74%[36] Cash Flow - Net cash flow from operating activities decreased by 34.79% to CNY 109,477,986.68, down from CNY 167,896,816.35 in the previous year[17] - Cash flow from investing activities decreased by 249.18%, primarily due to increased payments for pending equity[19] - The cash inflow from operating activities totaled CNY 9,793,709,617.80, an increase of 3.2% compared to CNY 9,490,023,016.36 in the previous period[46] - The cash outflow for investing activities was CNY 66,072,237.86, compared to CNY 54,382,937.71 in the previous period, resulting in a net cash flow from investing activities of -CNY 52,475,489.73, worsening from -CNY 15,028,363.89[47] - The cash inflow from financing activities reached CNY 5,061,920,115.16, an increase of 26% from CNY 4,019,349,217.88 in the previous period[47] - The net cash flow from financing activities improved to CNY 121,377,969.99, compared to a negative CNY 599,688,019.97 in the same period last year[47] - The total cash and cash equivalents at the end of the period were CNY 1,140,882,786.80, significantly up from CNY 533,008,970.87 at the end of the previous period[47] Assets and Liabilities - The company's total assets increased by 1.31% to CNY 36,728,073,881.49 from CNY 36,252,275,970.38 at the end of the previous year[17] - The total liabilities amounted to 30,562,048,972.47, compared to 30,141,845,242.23 in the previous period, indicating an increase of about 1.39%[33] - The total equity attributable to shareholders reached 4,755,846,194.56, up from 4,690,953,764.63, reflecting a growth of approximately 1.39%[33] - Current assets rose to ¥32,051,719,445.36, up from ¥31,524,548,826.78, indicating an increase of about 1.67%[57] - Short-term borrowings increased to ¥11,979,237,816.28 from ¥11,410,259,205.03, representing a growth of approximately 4.98%[57] - Accounts payable increased to ¥7,976,771,100.23 from ¥7,912,296,527.04, showing an increase of about 0.81%[57] - Other payables decreased to ¥6,176,220,199.51 from ¥6,288,109,695.49, reflecting a decline of approximately 1.78%[57] Expenses - The company’s research and development expenses were 11,339,139.83, slightly decreased from 11,543,209.87, showing a reduction of about 1.77%[35] - The sales expenses increased to 419,809,578.57 from 381,096,502.80, marking an increase of approximately 10.14%[35] - The company reported a 71.64% increase in income tax expenses, attributed to increased profitability of certain subsidiaries[19] Investments - Investment income rose by 304.05% due to gains from the disposal of subsidiaries[11] - The company reported a 686.58% increase in gains from asset disposals compared to the previous period, primarily due to increased fixed asset disposals by subsidiaries[50] - Construction in progress increased by 32.52% compared to the beginning of the year, mainly due to investments in subsidiary projects[19] - Long-term equity investments rose to ¥214,768,033.04 from ¥212,440,678.49, indicating a growth of about 1.09%[57] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 145,957[56] - The company received CNY 584,426.56 in tax refunds, a decrease of 82.1% from CNY 3,265,018.90 in the previous period[46]

Financial Performance - The company reported a total revenue of 1.5 billion RMB for the year 2022, representing a year-over-year increase of 10%[33] - The company reported a revenue of 46,799.96 million for the year 2022, with a significant increase compared to previous periods[143] - The company reported a revenue of 8,900 million for the year ending December 30, 2021, indicating a strong performance[149] - The company has set a performance guidance for the upcoming year, aiming for a revenue growth of approximately 10%[145] - The company has set a performance guidance of 2,000 million for the next quarter, aiming for steady growth[149] User Engagement - User data indicates a growth in active users by 15% compared to the previous year, reaching 2 million active users[33] - User data indicates a steady growth in customer base, although exact figures were not provided[145] - The company reported a 20% increase in user data engagement compared to the previous year, showcasing its growing customer base[151] Market Expansion - The company is expanding its market presence in Southeast Asia, targeting a 20% market share by 2025[33] - The company plans to expand its market presence with new product launches and technological advancements in the upcoming fiscal year[151] - The company plans to invest 200 million RMB in digital transformation initiatives over the next three years[33] - The company is focusing on research and development to innovate new medical technologies and improve existing products[152] - The company is exploring new technologies to improve operational efficiency and product offerings[138] Research and Development - Research and development expenses increased by 30% in 2022, focusing on new drug formulations and technologies[33] - The company has ongoing research and development efforts, with new product launches expected in the upcoming quarters[137] - The company is focusing on research and development of new technologies to enhance its product offerings[145] Strategic Acquisitions - The company has completed two strategic acquisitions in 2022, enhancing its product portfolio and market reach[33] - The company has completed several acquisitions to strengthen its market position and diversify its product portfolio[151] - The company is accelerating mergers and acquisitions, which presents challenges in management due to the complexity of the organizational structure and the integration of new entities[177] Financial Health - The company has established a strong financial position with a focus on maintaining liquidity and managing debt effectively[137] - The company reported a total debt of 4,019.63 million as of the latest financial update[118] - The company has a total of 9,300 million in contingent liabilities as of March 2022[123] - The company has a total of 30,000 million in liabilities as of December 22, 2022, reflecting its financial commitments[152] - The company has secured guarantees for its debts, indicating a strong financial backing[143] Corporate Governance - The internal control system of the company is reported to be operating well, with no significant defects identified during the 2022 internal control evaluation[47] - The company has maintained its internal control and governance structure, ensuring compliance and oversight by the board and supervisory committee[45] - The company has a commitment to protect the interests of minority shareholders and comply with relevant regulations[92] Social Responsibility - The company actively fulfilled its social responsibilities by providing medical support and donating cash, medicines, and materials during the reporting period[60] - The company made donations totaling 13.00 million CNY to Yangguang Ronghe Hospital and 360.00 million CNY in medical equipment to Hanchuan City[87] - The company has made donations of 10.00 million CNY for educational support in Anqing City and 9.00 million CNY for facility construction in Liantang Town, Pucheng County[89] Legal and Compliance Issues - The company is currently involved in a legal dispute regarding a share transfer contract, with a court freezing 30% of the shares held by a major shareholder[194] - The company has not engaged in entrusted financial management or entrusted loans during the reporting period[192][193] Share Structure - The company has a total share capital of 2,750,833,257 shares, with a 100% ownership structure, and an increase of 1,624,698 shares in locked-up shares due to the resignation of a director[174] - The total number of restricted shares before the change was 129,633,714, accounting for 4.71% of total shares, which increased to 131,258,412, representing 4.77% after the change[197] - There were no new shares issued or stock dividends during the reporting period[197]

Group 1: Company Overview and Business Strategy - The company focuses on two main business areas: pharmaceutical manufacturing and pharmaceutical commercial circulation, aiming for balanced development in both sectors [2][3]. - Future growth in pharmaceutical manufacturing will leverage R&D advantages and enhance the commercialization of innovative results, while maintaining a flexible marketing strategy [3][4]. Group 2: Market Development and Expansion - The company plans to solidify existing markets while actively exploring emerging and potential markets through resource integration and centralized operations [4][5]. - Acquisitions in new regions will prioritize operational qualifications, team integrity, and brand influence of local companies [4]. Group 3: Financial Performance and Challenges - The sales revenue from the company's product line, including OTC products and health products, accounts for approximately 0.35% of the total pharmaceutical manufacturing sales [5]. - The overall gross margin in the pharmaceutical manufacturing sector has declined, with a reported decrease of 0.44 percentage points in the first quarter of 2014 compared to the previous months, attributed to rising material costs and regulatory price controls [5].

Group 1: Company Overview - Shenzhen Haiwang Biological Engineering Co., Ltd. is engaged in pharmaceutical commerce, pharmaceutical industry, and innovative development [1][2]. - The company has been transitioning from traditional pharmaceuticals to new types of pharmaceuticals, with a current net profit margin of 1.6% [3]. Group 2: Business Strategy - Haiwang Biological has been focusing on centralized procurement and sunshine distribution since 2003, with significant growth in profit margins expected as the company learns from its subsidiaries [3][4]. - The company is exploring horizontal expansion in specific regions and vertical integration with hospitals, which includes centralized distribution and professional pharmacy services [4][5]. Group 3: Market Position and Competition - The company aims to maintain a competitive edge in the market, with a sales target of 20 billion expected to saturate the terminal market [4][5]. - Haiwang Biological has a strong confidence in its products due to patent support and a high success rate in bidding processes [5][6]. Group 4: Future Plans - There are plans for potential acquisitions of hospitals and other medical resources, as demonstrated by a recent investment in a hospital project [5][6]. - The company is also looking to expand its online presence through O2O (Online to Offline) strategies, leveraging its extensive product range [6][7].

Group 1: Company Overview and Market Position - Shenzhen Haiwang Biological Engineering Co., Ltd. is actively expanding its market presence, particularly in East China, with significant sales in Shandong province, where it ranks among the top in sales volume [2] - The company has established a strong market position in Shandong since entering in 2003, with continuous growth in sales and tax revenue, solidifying its leading advantage in the region [2] - Haiwang has recently entered the Jiangsu market, currently operating one subsidiary in Nantong for pharmaceutical logistics [2] Group 2: Business Model and Competitive Advantages - The "Sunshine Centralized Distribution" model offers higher gross margins compared to other pharmaceutical distribution models due to centralized procurement and unified distribution, enhancing bargaining power and operational efficiency [3] - This model differs from traditional hospital sales by ensuring comprehensive supply guarantees for all types of hospital products, fostering closer strategic partnerships with hospitals [4] - The use of quantum dot materials in POCT (Point of Care Testing) projects provides a competitive edge in terms of luminous efficiency and stability, positioning the company favorably against competitors [5] Group 3: Strategic Development and Future Plans - Haiwang is exploring innovative business models in response to potential threats from e-commerce and pharmacies, with pilot implementations in some regions [5] - The strategic goal is to become a leading regional modern pharmaceutical logistics enterprise, focusing on professional drug and consumable distribution and management [6] - The company is committed to expanding its logistics capabilities and exploring new business avenues, including third-party logistics and pharmaceutical e-commerce [6] Group 4: Compliance and Information Disclosure - The company adheres strictly to information disclosure regulations, ensuring that all disclosures are truthful, accurate, complete, timely, and fair, with no significant undisclosed information leaks [6]

Group 1: Company Overview - The company has divested from loss-making pharmaceutical manufacturing enterprises to enhance asset liquidity and profitability, ensuring stable development in the pharmaceutical sector [3] - Currently, the company maintains a product portfolio of over 500 items, including chemical drugs, traditional Chinese medicine, biological drugs, and health food [3] Group 2: Business Strategy - The company enters new regions for pharmaceutical distribution through acquisitions or joint ventures with local companies, adapting to the local business environment [3] - The extension services in the pharmaceutical business are not yet significant but are seen as a future growth direction, focusing on smart management to improve efficiency [4] Group 3: Market Opportunities - The health technology subsidiary has seen rapid growth, with revenue from infant formula and maternal and infant products increasing from 200 million to over 400 million from 2011 to 2014 [4] - The company plans to leverage the newly announced two-child policy to further promote its maternal and infant product lines, aiming to establish them as new profit growth points [4] Group 4: Compliance and Disclosure - The company adheres strictly to information disclosure regulations, ensuring that all disclosed information is true, accurate, complete, timely, and fair, with no significant undisclosed information leaks [5]

Group 1: Product Advantages - The company's Tegio tablets are the first to be marketed in tablet form, providing a competitive edge over existing capsule forms [1][2] - Clinical trials demonstrate the Tegio tablets' efficacy, tolerability, and convenience, ensuring safety and effectiveness [2] - The tablet formulation minimizes unnecessary excipients, reducing quality and safety risks associated with non-essential ingredients [2] Group 2: Market Position and Strategy - The company has a strong competitive position in tenders, with a high success rate in winning bids due to the unique tablet formulation [2] - The market potential for Tegio tablets is optimistic, with numerous niche markets and relatively few competitors [2] - The company plans to enhance sales through academic promotion and the establishment of a specialized sales team [2] Group 3: Future Expansion Plans - The company is exploring opportunities for private capital investment in healthcare, following successful participation in a hospital project [3] - Future collaborations may include various forms such as equity participation or partnerships, depending on regulatory conditions [3] - The company aims to replicate successful distribution models from its Nanyang subsidiary across other subsidiaries to improve overall profit margins [3]

Group 1: Company Overview and Strategy - The company introduced its basic situation, including strategic development, pharmaceutical commerce, pharmaceutical industry, centralized distribution, and innovation [2] - The pharmaceutical commercial business started in 2003 with the acquisition of Weifang Pharmaceutical Station, and has grown significantly since then [3] Group 2: Challenges and Solutions - The company faces challenges in expanding its pharmaceutical business, including funding, personnel, and standardization of pharmacies [3] - The company emphasizes that overcoming difficulties is essential for building a great enterprise, and it believes in the future of its centralized distribution model [3] Group 3: Internet Integration and Future Plans - The company is exploring the integration of "Internet +" into its operations, recognizing the vast potential of the pharmaceutical industry [4] - There are plans for external development, including acquisitions, to adapt to rapid industry changes and capitalize on existing resources [4] Group 4: Automation and Information Technology - The company is developing its own automation and information technology solutions rather than outsourcing, with a focus on pharmacy automation and hospital needs [5] - Recent projects include a significant investment of approximately 14 million for the Zaozhuang Maternal and Child Health Hospital reconstruction and around 4 million for an automation project in Weihai [7] Group 5: Collaboration with Hospitals - The company is preparing to collaborate with hospitals, considering the government's policies on hospital equity and management flexibility [6] - A recent partnership with Nanyang Central Hospital involved a shareholding transformation, aligning with national policies to enhance hospital management [6]

深圳市海王生物工程股份有限公司 投资者关系活动记录表 编号：2016-05 | --- | --- | |----------------|---------------------------------| | | | | 投资者关系活动 | 特定对象调研 □分析师会议 | | 类别 | □媒体采访 □业绩说明会 | | | 新闻发布会 □路演活动 | | | □现场参观 | | | | | 参与单位名称 | 来访机构 | | | 国信证券 邓周宇、欧阳科伟、杨辉 | | | 银河证券 全 铭 | | | 华泰资管 万永涛 | | | 中科沃土 宋佳蕾 | | | 创新投资 谭权胜 | | | 财富证券 陈 博 | | | 民生证券 刘 淼 | | | 前海德润资本 甘和平、王姣月 | | | 国海证券 盛丽华 | | | 稻草人投资 方美玲 | | | 万杉资本 谷子樵 | | | 等机构与研究人员 | | --- | --- | --- | |----------------|----------------------------------|----------------------------- ...